|
|
||||||||
Department of Immunology, The Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne, United Kingdom
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
In the present report, we used two CD4+ T cell hybridomas specific for two distinct T cell epitopes of the surface fibrillar M5 protein of Streptococcus pyogenes, which is the major virulence factor and protective Ag of group A streptococci (28), to study the mechanisms of bacterial Ag processing in murine macrophages. We have previously shown that both epitopes are processed from viable streptococci for MHC-II-restricted presentation to specific CD4+ T cell clones and T cell hybridomas (29, 30, 31, 32). Evidence is presented here that presentation of distinct N-terminal and C-terminal epitopes is segregated into recycling and classical MHC-II processing pathways, respectively.
| Materials and Methods |
|---|
|
|
|---|
All culture media ingredients, chemicals, and inhibitors were
purchased from Sigma Chemical (Dorset, U.K.) except for tyrphostin A25
(Calbiochem-Novabiochem, Nottingham, U.K.). All of the inhibitors,
solvents, and concentrations studied are shown in Table I
. All cells were grown in RPMI 1640
medium supplemented with 3.0 mM L-glutamine, 0.05 mM
2-ME, and 10% FBS (v/v).
|
The murine macrophage-like cell line J774A.1
(H-2d, ATCC TIB67; American Type Culture Collection
(ATCC), Bethesda, MD) was used in all experiments. T cell hybridomas
(HX17 and HY2) were developed by polyethylene glycol (PEG) fusion of
two M5 protein-specific T cell clones (X17 and Y2) with BW5147
(TCR
-ß-) cells (a gift from Dr. P
Marrack, Departments of Microbiology and Immunology and Medicine,
University of Colorado Health Sciences Center, Denver, CO). The
expression of the TCR
ß-chains on the T cell hybridomas was
confirmed by flow cytometry (data not shown). The specificity of T cell
hybridomas HX17 and HY2 for epitopes 1731/Ed and
308319/Ad of group A streptococcal type 5 M protein,
respectively, was reported previously (32).
The Manfredo strain of S. pyogenes, obtained from Dr. Michael A. Kehoe, Department of Microbiology, Newcastle University, Newcastle upon Tyne, U.K. was grown overnight in RPMI 1640 with 10% FBS, and the concentration was adjusted spectrophotometrically to 3 x 108/ml (A600 = 0.6).
Recombinant M5 protein (rM5) and synthetic peptides
The cloning and expression of rM5 from type 5 S. pyogenes strain Manfredo in Escherichia coli LE392 and the sequence of the cloned gene have been described previously (29, 33). The following synthetic peptides, covering two T cell epitopes on the M5 protein of S. pyogenes, were purchased from the Molecular Biology Facility, Newcastle University, Newcastle upon Tyne, U.K.: 1) 1533 peptide containing epitope 1731/Ed; and 2) 300319 peptide covering epitope 308319/Ad (29). Peptides were used as HPLC-purified preparations, and purity was confirmed by mass spectrometry.
Ag processing and presentation assay
J774A.1 macrophages (6 x 104/well) were allowed to adhere to the bottom of 48-well plates (Bibby Sterilin, Staffordshire, U.K.) for 1 h; the cells were pretreated with inhibitors for 30 min, except if stated otherwise; and viable streptococci (3 x 106/well) or rM5 (1.0 µg/ml) were added. After 1 h of incubation at 37°C in a humidified CO2 incubator, nonphagocytozed bacteria were killed with gentamicin (50 µg/ml), and the plates were incubated for an additional 3 h. The macrophages were fixed with 1.0% paraformaldehyde for 10 min, the reaction was stopped with ice-cold 0.06% Gly-Gly (34), and the wells were washed with PBS to remove the extracellular bacteria, the fixative, and any remaining inhibitors. T cell hybridoma cells were added (3 x 104/well), the plates were incubated at 37°C in a CO2 incubator for 24 h, and the culture supernatants were collected and frozen at -20°C overnight before the IL-2 assay. In some experiments, J774A.1 cells were pretreated with anti-MHC-II mAb M5/114.15.2 (anti-Aßb,d,q; anti-Ed,k), used as ammonium sulfate precipitate of culture supernatant from hybridoma TIB120 obtained from ATCC, for 30 min before challenging with Ag. After a 4-h incubation, macrophages were either fixed or not before adding T cell hybridomas.
Particular attention was paid to ensure that any inhibition observed did not result from the nonspecific activity of inhibitors. Synthetic peptide controls were performed for each dilution of the inhibitor, and the viability of J774A.1 cells before fixation was confirmed in all experiments. The following controls were routinely used: 1) responses in the absence of inhibitors, 2) background responses in the absence of Ag, and 3) presentation of the relevant peptide (4.0 µg/ml). The optimal concentrations of the fixative, inhibitors, and the cells involved, as well as the timing, were determined in separate experiments. All experiments were repeated at least three times, and the data for a representative experiment are shown.
IL-2 assay
Culture supernatants (diluted 1:2) obtained from Ag processing assays were screened for IL-2 content, measured as the proliferative response of CTLL-2 cells (104/well). The assays were performed in flat-bottom 96-well Microtiter plates (Becton Dickinson, Cowley, Oxford, U.K.) on two separate occasions in duplicates for 24 h at 37°C in a humidified CO2 incubator. The cultures were pulse labeled overnight with 0.4 µCi of [3H]thymidine (TRA310, sp. act., 2.0 Ci/mmol; Amersham International, Buckinghamshire, U.K.) and harvested on glass fiber membranes, and radioactivity was quantitated using a direct beta counter (Matrix 9600, Packard Instrument, Meriden, CT).
Statistics
Descriptive statistics including calculations of the mean and the SE of the mean (SEM) were performed at p = 0.05 on an IBM-compatible PC using MicroSoft Excel 5.0 and Prism 2.0 software (GraphPad, San Diego, CA).
| Results |
|---|
|
|
|---|
The classical and recycling MHC-II processing pathways use different pools of MHC-II molecules, and thus can be distinguished according to their susceptibility to brefeldin A, which disrupts the Golgi network, and cycloheximide, which inhibits protein synthesis. Both inhibitors block the classical MHC-II processing pathway by preventing accumulation of newly synthesized MHC-II molecules in peptide-loading compartments (18, 20, 23, 35).
Brefeldin A inhibited processing of 308319 from viable
streptococci, but had no apparent effect on the processing of 1731
(Fig. 1
A). Similarly,
pretreatment of J774A.1 macrophages with cycloheximide for 2 h
eliminated presentation of 308319 and only partially blocked the
processing of 1731 from viable bacteria (Fig. 1
B).
The data support the interpretation that processing of viable
streptococci for 308319 presentation followed the classical MHC-II
pathway using newly synthesized MHC-II molecules and requiring
functional endoplasmic reticulum (ER)-Golgi transport. In contrast, the
data indicate that 1731 was presented by the recycling MHC-II
molecules independent of ER-Golgi communications.
|
Ag processing of two T cell epitopes involves different endocytic compartments
There is recent evidence suggesting that peptide loading can occur both in late endosomal and early endosomal compartments, which require newly synthesized or recycling MHC-II molecules, respectively (18, 20, 21, 27). Membrane transport from early to late endosomes has been shown to be dependent on microtubules and is regulated by protein kinases, GTP-binding proteins, and other proteins (17). Thus, we used metabolic inhibitors to distinguish between early and late endosomes as the main Ag processing compartments for viable streptococci.
Vinblastine disrupts the microtubule network, which is essential for
translocation of endocytosed Ags between early and late endosomes (36).
Presentation of 1731 from viable streptococci was not blocked by
vinblastine (Fig. 2
A),
pointing to early endosomes as the main Ag-processing compartment for
this epitope. In contrast, presentation of 308319 from bacteria was
consistently more dependent on functional microtubules, suggesting that
Ag processing of this epitope occurred mainly in late
endosomal/lysosomal compartments.
|
-phosphate of GTP and therefore bind and inactivate the
GDP-bound form of trimeric G proteins (37).
AlF4- profoundly blocked processing of
308319 from bacteria, implicating GTP-binding protein-dependent
endosomal transport in the processing of this epitope (Fig. 2
To distinguish between late endosomes and lysosomes as the
intracellular compartments used for processing of 308319, we used
tyrphostin A25, which blocks protein tyrosine kinase-dependent
regulation of endosomal transport between late endosomes and lysosomes
(38). Tyrphostin A25 did not reduce the level of presentation of
308319 (or M5 1731), indicating that bacterial processing of
308319 was confined to the late endosomal, rather than the lysosomal,
compartment (Fig. 2
C).
Processing of both epitopes from soluble rM5 resembled that observed for viable bacteria, except that 1731 presentation was inhibited by AlF4- anions, implying involvement of GTP-binding proteins. Presentation of synthetic peptides was unaffected by these inhibitors, except that 308319 was blocked by AlF4- anions.
Different kinetics of Ag presentation of two M5 T cell epitopes
Classical and recycling MHC-II pathways can be distinguished by
the kinetics of Ag presentation (23, 25). Figure 3
shows that presentation of 1731 was
detected from 15 min after challenge with streptococci, reaching a
plateau by 60 min, consistent with processing via the recycling MHC-II
pathway. In contrast, 308319 was processed more slowly and was
detectable from 60 min, with the level increasing up to 360 min,
consistent with processing via the classical MHC-II pathway.
Presentation of both epitopes from soluble rM5 and synthetic peptides
uniformly showed the slower kinetic patterns.
|
Distinct patterns of inhibitory activity of anti-MHC-II mAb TIB120
(specific for Aßb,d,q and Ed,k) was
observed for presentation of the two epitopes to specific T cells. If
J774A.1 cells were not fixed after challenge with viable streptococci,
presentation of both epitopes was completely blocked by anti-MHC-II mAb
(Fig. 4
), with 308319 being about 10
times more sensitive. However, if J774A.1 were fixed, TIB120 failed to
inhibit presentation of 1731 even at the highest concentrations used
(Fig. 4
A). The data on presentation of soluble rM5
protein and synthetic peptides were consistent with bacterial Ag
processing for presentation of both epitopes, suggesting a differential
sensitivity of the classical and recycling MHC-II pathways to
anti-MHC-II mAb.
|
| Discussion |
|---|
|
|
|---|
Morphologic studies revealed that most of the intracellular MHC-II molecules could be visualized by immunoelectron microscopy in the high density multivesicular or multilaminar endocytic compartments that express markers of late endosomes/lysosomes (MIIC) (18), and in low density endosomes (CIIV), which are devoid of lysosomal markers (39). MIIC are thought to metabolize most Ags for presentation by newly synthesized MHC-II molecules of the classical MHC-II processing pathway (16, 19, 27), while low density endosomes are involved in the presentation of some Ags by MHC-II molecules recycled from the cell surface, constituting the recycling MHC-II processing pathway (20, 21, 23, 24). In the current study, we showed that two T cell epitopes of a single protein on the bacterial surface were clearly routed to distinct Ag processing compartments in the course of bacterial Ag processing. The segregation mechanism of the two epitopes from the same protein for targeting to distinct MHC-II processing pathways is under investigation. Targeting to distinct processing pathways would be expected if an amino-terminal fragment of M5 that contains 1731 was enzymatically cleaved from the streptococcal surface (or from soluble rM5), separating it from the remaining fragment of M5 containing 308319, for entry into the early endosomal compartment. However, the differences may also lie in the primary structure of the epitopes and flanking amino acid sequences, which could influence peptide targeting or transport. The dose-response titrations of the two T cell hybridomas are superimposable (data not shown), indicating that the affinity of T cell receptors is unlikely to account for the differences seen. We do not know whether these differences are dependent on the MHC haplotype, as our results are confined to the H-2d mice. The two epitopes studied bind different MHC-II molecules: 1731 to Ed and 308319 to Ad, although other reports have not shown preferential usage of a particular MHC-II molecule for presentation via the recycling vs the classical MHC-II pathway (20, 21, 23, 24, 25).
Our study also revealed that bacterial Ag processing of 1731 and 308319 exhibited differential sensitivity to blocking with anti-MHC-II mAb, which was particularly pronounced in fixed macrophages. Thus, presentation of 308319 was completely blocked, whereas presentation of 1731 was not inhibited by anti-MHC-II mAb, suggesting that classical and recycling MHC-II pathways are differentially blocked by anti-MHC-II Abs. The mechanisms of this differential blocking are under investigation.
Our demonstration that epitopes from the same protective Ag on the surface of an intact bacterial pathogen can be processed by different MHC-II pathways has implications for Ag delivery systems used for the development of vaccines.
Note added in proof. The authors have since published the following related study: Deluig, A. A., and J. H. Robinson. 1998. Different endosomal proteolysis requirements for antigen processing of two T-cell epitopes of the M5 protein from viable streptococcus pyogenes. J. Biol. Chem. 273:3291.
| Acknowledgments |
|---|
-ß-) cells, M. A.
Kehoe, Department of Microbiology, Newcastle University, Newcastle
upon Tyne, U.K. for providing the Manfredo strain of S.
pyogenes and recombinant M5 protein, and I. Holen,
Department of Human Metabolism and Clinical Biochemistry, Sheffield
University Medical School, Sheffield, U.K. for useful advice on
inhibitors. | Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. John H. Robinson, Department of Immunology, The Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH, U.K. E-mail address: ![]()
3 Abbreviations used in this paper: MHC-II, class II MHC; MIIC, major histocompatibility class II loading compartment; ER, endoplasmic reticulum; Ii, invariant chain; rM5, recombinant streptococcal type 5 M protein; AlF4-, aluminium fluoride anion. ![]()
Received for publication October 17, 1997. Accepted for publication January 30, 1998.
| References |
|---|
|
|
|---|
differentially regulates antigen-processing function in distinct endocytic compartments of macrophages with constitutive expression of class II major histocompatibility complex. Immunology 88:68.[Medline]
-chain does not require processing. J. Immunol. 140:1063.[Abstract]
and interleukin-10 have cross-regulatory roles in modulating the class I and class II-mediated presentation of epitopes of Listeria monocytogenes by infected macrophages. J. Interferon Cytokine Res. 16:547.[Medline]
This article has been cited by other articles:
![]() |
J. A. Musson, N. Walker, H. Flick-Smith, E. D. Williamson, and J. H. Robinson Differential Processing of CD4 T-cell Epitopes from the Protective Antigen of Bacillus anthracis J. Biol. Chem., December 26, 2003; 278(52): 52425 - 52431. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Sinnathamby and L. C. Eisenlohr Presentation by Recycling MHC Class II Molecules of an Influenza Hemagglutinin-Derived Epitope That Is Revealed in the Early Endosome by Acidification J. Immunol., April 1, 2003; 170(7): 3504 - 3513. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Delvig, J. J. Lee, Z. M. A. Chrzanowska-Lightowlers, and J. H. Robinson TGF-{beta}1 and IFN-{gamma} cross-regulate antigen presentation to CD4 T cells by macrophages J. Leukoc. Biol., July 1, 2002; 72(1): 163 - 166. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. W. Cunningham Pathogenesis of Group A Streptococcal Infections Clin. Microbiol. Rev., July 1, 2000; 13(3): 470 - 511. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Ramachandra and C. V. Harding Phagosomes Acquire Nascent and Recycling Class II MHC Molecules but Primarily Use Nascent Molecules in Phagocytic Antigen Processing J. Immunol., May 15, 2000; 164(10): 5103 - 5112. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |